Drug Patents Expiring in 2024

1. Drug name - ABILIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Jun, 2024

(1 year, 8 months from now)

US7115587 OTSUKA Aripiprazole complex formulation and method Jul, 2024

(1 year, 9 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method Jul, 2024

(1 year, 9 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Dec, 2024

(2 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Treatment of schizophrenia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

2. Drug name - ABILIFY MAINTENA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method Oct, 2024

(2 years from now)

US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method Oct, 2024

(2 years from now)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method Oct, 2024

(2 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
300MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
300MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

3. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof Jun, 2024

(1 year, 8 months from now)

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

4. Drug name - ABRAXANE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8314156

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Jun, 2024

(1 year, 8 months from now)

US8138229

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Jun, 2024

(1 year, 8 months from now)

US7923536

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Jun, 2024

(1 year, 8 months from now)

US7820788 ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Oct, 2024

(2 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of lung cancer; treatment of breast cancer; treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

5. Drug name - ACULAR LS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207215 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8377982 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8648107 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8946281 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8906950 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US9216167 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8541463 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain May, 2024

(1 year, 7 months from now)

US8541463

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Nov, 2024

(2 years from now)

US8207215

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Nov, 2024

(2 years from now)

US8377982

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Nov, 2024

(2 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: A method of controlling postoperative ocular pain and burning/stinging in a patient; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of treating ocular pain; A method of treating or preventing ocular pain and burning; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or reducing ocular pain and burning/stinging

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.4% SOLUTION/DROPS;OPHTHALMIC Prescription

6. Drug name - ACUVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8992952 ALLERGAN Compositions for delivery of therapeutics into the eyes and methods for making and using same Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.45% SOLUTION/DROPS;OPHTHALMIC Prescription

7. Drug name - ADASUVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9370629 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same May, 2024

(1 year, 7 months from now)

US8991387 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same May, 2024

(1 year, 7 months from now)

US7458374 ALEXZA PHARMS Method and apparatus for vaporizing a compound Aug, 2024

(1 year, 10 months from now)

US7537009 ALEXZA PHARMS Method of forming an aerosol for inhalation delivery Oct, 2024

(2 years from now)

Drugs and Companies using LOXAPINE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
10MG POWDER;INHALATION Prescription

8. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024 TEVA PHARM Process for preparing a medicament Sep, 2024

(1 year, 11 months from now)

US9987229 TEVA PHARM Process for preparing a medicament Sep, 2024

(1 year, 11 months from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

9. Drug name - ALDARA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7696159 BAUSCH Treatment for basal cell carcinoma
Apr, 2024

(1 year, 6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159

(Pediatric)

BAUSCH Treatment for basal cell carcinoma Oct, 2024

(2 years from now)

Drugs and Companies using IMIQUIMOD ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
5% CREAM;TOPICAL Prescription

10. Drug name - ALIQOPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511041 BAYER HEALTHCARE Fused azole-pyrimidine derivatives
May, 2024

(1 year, 7 months from now)

More Information on Dosage
Strength Dosage Availability
60MG/VIAL POWDER;INTRAVENOUS Prescription

11. Drug name - ALOXI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947724 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US9066980 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US8729094 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US9457020 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US8518981 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US9439854 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US7947725 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US8598218 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US9457021 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US9125905 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US7960424 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US9173942 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US8598219 HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jan, 2024

(1 year, 4 months from now)

US8518981

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US7960424

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US7947725

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US7947724

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US8598218

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US9173942

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US9439854

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US9457020

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US8729094

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US8598219

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US9125905

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US9457021

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

US9066980

(Pediatric)

HELSINN HLTHCARE Liquid pharmaceutical formulations of palonosetron Jul, 2024

(1 year, 9 months from now)

Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Prevention of chemotherapy-induced nausea and vomiting

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) INJECTABLE;INTRAVENOUS Discontinued
EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) INJECTABLE;INTRAVENOUS Discontinued

12. Drug name - ALPHAGAN P

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components Mar, 2024

(1 year, 5 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SOLUTION/DROPS;OPHTHALMIC Prescription

13. Drug name - ALTABAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191 ALMIRALL Process, salts, composition and use Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

14. Drug name - AMITIZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7795312 SUCAMPO PHARMA LLC Method for treating abdominal discomfort Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using LUBIPROSTONE ingredient

Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
8MCG CAPSULE;ORAL Prescription
24MCG CAPSULE;ORAL Prescription

15. Drug name - ANJESO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10463673 BAUDAX Nanoparticulate meloxicam formulations Feb, 2024

(1 year, 4 months from now)

US10471067 BAUDAX Nanoparticulate meloxicam formulations Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
30MG/ML (30MG/ML) SOLUTION;INTRAVENOUS Prescription

16. Drug name - ARIKAYCE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802137 INSMED INC Sustained release of antiinfectives Apr, 2024

(1 year, 6 months from now)

US9827317 INSMED INC Sustained release of antiinfectives Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 590MG BASE/8.4ML SUSPENSION, LIPOSOMAL;INHALATION Prescription

17. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024 TEVA PHARM Process for preparing a medicament Sep, 2024

(1 year, 11 months from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

18. Drug name - ATRIPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744181 GILEAD SCIENCES Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US8592397 GILEAD SCIENCES Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US8716264 GILEAD SCIENCES Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US9457036 GILEAD SCIENCES Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; treatment of hiv-1 infection in adults

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
600MG;200MG;300MG TABLET;ORAL Prescription

19. Drug name - AURYXIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8338642 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 4 months from now)

US9757416 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 4 months from now)

US9328133 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 4 months from now)

US7767851 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same
Feb, 2024

(1 year, 4 months from now)

CN1751056A KERYX BIOPHARMS Ferric Organic Compound, Its Preparation Method And Its Application
Feb, 2024

(1 year, 4 months from now)

CN100386336C KERYX BIOPHARMS Ferric Organic Compound, Its Preparation Method And Its Application
Feb, 2024

(1 year, 4 months from now)

IN244119B KERYX BIOPHARMS Ferric Organic Compounds, Uses Thereof And Methods Of Making Same
Feb, 2024

(1 year, 4 months from now)

IN200500944P3 KERYX BIOPHARMS Ferric Organic Compounds, Uses Thereof And Methods Of Making Same
Feb, 2024

(1 year, 4 months from now)

EP1601680A4 KERYX BIOPHARMS Ferric Organic Compounds, Uses Thereof And Methods Of Making Same
Feb, 2024

(1 year, 4 months from now)

EP1601680B8 KERYX BIOPHARMS Methods Of Making Ferric Organic Compounds
Feb, 2024

(1 year, 4 months from now)

EP1601680A2 KERYX BIOPHARMS Methods Of Making Ferric Organic Compounds
Feb, 2024

(1 year, 4 months from now)

EP1601680B1 KERYX BIOPHARMS Methods Of Making Ferric Organic Compounds
Feb, 2024

(1 year, 4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050316 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same Feb, 2024

(1 year, 4 months from now)

US8299298 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same Feb, 2024

(1 year, 4 months from now)

US8609896 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same Feb, 2024

(1 year, 4 months from now)

US8754257 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same Feb, 2024

(1 year, 4 months from now)

US8754258 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same Feb, 2024

(1 year, 4 months from now)

US8901349 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same Feb, 2024

(1 year, 4 months from now)

US8846976 KERYX BIOPHARMS Ferric organic compounds, uses thereof and methods of making same Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using FERRIC CITRATE ingredient

Treatment: Control of serum phosphorous levels

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 210MG IRON TABLET;ORAL Prescription

20. Drug name - AUVI-Q

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8361029 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery Nov, 2024

(2 years from now)

US9833573 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8920377 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.15MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.3MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription

21. Drug name - BOSULIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(1 year, 6 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription
EQ 400MG BASE TABLET;ORAL Prescription
EQ 500MG BASE TABLET;ORAL Prescription

22. Drug name - BRILINTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(2 years from now)

EP1135391B1 ASTRAZENECA Novel Triazolo(4,5-D)Pyrimidine Compounds
Dec, 2024

(2 years from now)

EP1135391A1 ASTRAZENECA Novel Triazolo(4,5-D)Pyrimidine Compounds
Dec, 2024

(2 years from now)

Drugs and Companies using TICAGRELOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription

23. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

24. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

25. Drug name - CABOMETYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8497284 EXELIXIS INC C-met modulators and method of use Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Treatment of renal cell carcinoma; treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; treatment of advanced renal cell carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

26. Drug name - CHILDREN'S ADVIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition May, 2024

(1 year, 7 months from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/5ML SUSPENSION;ORAL Over the counter

27. Drug name - CHILDREN'S ADVIL ALLERGY SINUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition May, 2024

(1 year, 7 months from now)

More Information on Dosage
Strength Dosage Availability
1MG/5ML;100MG/5ML;15MG/5ML SUSPENSION;ORAL Over the counter

28. Drug name - CHLORAPREP ONE-STEP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6991394 BECTON DICKINSON CO Liquid applicator with a mechanism for fracturing multiple ampoules Jan, 2024

(1 year, 4 months from now)

More Information on Dosage
Strength Dosage Availability
2%;70% (3ML) SPONGE;TOPICAL Over the counter
2%;70% (10.5ML) SPONGE;TOPICAL Over the counter
2%;70% (26ML) SPONGE;TOPICAL Over the counter
2%;70% (1ML) SPONGE;TOPICAL Over the counter
2%;70% (1.5ML) SPONGE;TOPICAL Over the counter

29. Drug name - CHLORHEXIDINE GLUCONATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7066916 SAGE PRODS Disinfectant delivery system, and method of providing alcohol-free disinfection Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Treatment: Disinfection of patient skin prior to an invasive procedure

Dosage: CLOTH;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% CLOTH;TOPICAL Over the counter

30. Drug name - COMBIVENT RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties Aug, 2024

(1 year, 10 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE/INH;0.02MG/INH SPRAY, METERED;INHALATION Prescription

31. Drug name - COMPLERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9457036 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US9744181 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US8592397 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US8716264 GILEAD SCIENCES INC Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

More Information on Dosage
Strength Dosage Availability
200MG;EQ 25MG BASE;300MG TABLET;ORAL Prescription

32. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7462626 NALPROPION Compositions for affecting weight loss Jul, 2024

(1 year, 9 months from now)

US8815889 NALPROPION Compositions and methods for increasing insulin sensitivity Jul, 2024

(1 year, 9 months from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: For chronic weight management for treating overweight or obesity; For effect on blood glucose parameters in patients with insulin resistance

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

33. Drug name - DALIRESP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618142 ASTRAZENECA Process for the preparation of roflumilast Mar, 2024

(1 year, 5 months from now)

US8604064 ASTRAZENECA Process for the preparation of roflumilast Mar, 2024

(1 year, 5 months from now)

US8536206 ASTRAZENECA Process for the preparation of roflumilast Mar, 2024

(1 year, 5 months from now)

Drugs and Companies using ROFLUMILAST ingredient

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
250MCG TABLET;ORAL Prescription
500MCG TABLET;ORAL Prescription

34. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

35. Drug name - DEXILANT SOLUTAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

36. Drug name - DEXTENZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: NA

Dosage: INSERT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.4MG INSERT;OPHTHALMIC Prescription

37. Drug name - DIFFERIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737181 GALDERMA LABS LP Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using ADAPALENE ingredient

Treatment: NA

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.3% GEL;TOPICAL Prescription

38. Drug name - DIFICID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586551

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Jan, 2024

(1 year, 3 months from now)

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

39. Drug name - DIPRIVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(2 years from now)

Drugs and Companies using PROPOFOL ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
10MG/ML INJECTABLE;INJECTION Prescription

40. Drug name - DUAVEE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6479535 WYETH PHARMS 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations May, 2024

(1 year, 7 months from now)

Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient

Treatment: Prevention of postmenopausal osteoporosis; treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE;0.45MG TABLET;ORAL Prescription

41. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

42. Drug name - DUTREBIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2024

(1 year, 6 months from now)

More Information on Dosage
Strength Dosage Availability
150MG;EQ 300MG BASE TABLET;ORAL Discontinued

43. Drug name - DYMISTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids Feb, 2024

(1 year, 4 months from now)

More Information on Dosage
Strength Dosage Availability
0.137MG/SPRAY;0.05MG/SPRAY SPRAY, METERED;NASAL Prescription

44. Drug name - ENTRESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7468390

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition May, 2024

(1 year, 7 months from now)

More Information on Dosage
Strength Dosage Availability
24MG;26MG TABLET;ORAL Prescription
49MG;51MG TABLET;ORAL Prescription
97MG;103MG TABLET;ORAL Prescription

45. Drug name - ENVARSUS XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586084 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8889186 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8623411 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8889185 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US7994214 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8591946 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US9763920 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8623410 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8617599 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US9757362 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US10548880 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US9161907 VELOXIS PHARMS INC Modified release compositions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

US8486993 VELOXIS PHARMS INC Solid dispersions comprising tacrolimus Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using TACROLIMUS ingredient

Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; prophylaxis of organ rejection in de novo transplant patient

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.75MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 4MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

46. Drug name - EPIDUO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7964202 GALDERMA LABS LP Method for treatment of common acne Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1%;2.5% GEL;TOPICAL Prescription

47. Drug name - EQUETRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253 VALIDUS PHARMS Methods for the treatment of bipolar disorder using carbamazepine May, 2024

(1 year, 7 months from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
200MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
300MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

48. Drug name - EVEKEO ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580 ARBOR PHARMS LLC Taste-masked pharmaceutical compositions Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
5MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
10MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
15MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
20MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription

49. Drug name - EVOCLIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7374747 MYLAN Pharmaceutical foam Jan, 2024

(1 year, 3 months from now)

US7141237 MYLAN Pharmaceutical foam Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Treatment: Treatment of acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% AEROSOL, FOAM;TOPICAL Prescription

50. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8313466 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8608698 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery Nov, 2024

(2 years from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

51. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8608698 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8425462 KALEO INC Devices, systems, and methods for medicament delivery Nov, 2024

(2 years from now)

US9737669 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8361029 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US8313466 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US9056170 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US10314977 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US10737028 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

US7918823 KALEO INC Devices, systems and methods for medicament delivery Nov, 2024

(2 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

52. Drug name - EXSERVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 MITSUBISHI HOLDINGS Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions Feb, 2024

(1 year, 4 months from now)

US8603514 MITSUBISHI HOLDINGS Uniform films for rapid dissolve dosage form incorporating taste-masking compositions Apr, 2024

(1 year, 6 months from now)

More Information on Dosage
Strength Dosage Availability
50MG FILM;ORAL Prescription

53. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

54. Drug name - FENOGLIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173847 SALIX Tablet comprising a fibrate Oct, 2024

(2 years from now)

US8481078 SALIX Solid dosage form comprising a fibrate Oct, 2024

(2 years from now)

US8124125 SALIX Solid dosage form comprising a fibrate Oct, 2024

(2 years from now)

US7658944 SALIX Solid dosage form comprising a fibrate Dec, 2024

(2 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Treatment: Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides; For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription
120MG TABLET;ORAL Prescription

55. Drug name - FENTORA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119158 CEPHALON Effervescent oral fentanyl dosage form and methods of administering fentanyl Dec, 2024

(2 years from now)

US8092832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering Dec, 2024

(2 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.2MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.3MG BASE TABLET;BUCCAL, SUBLINGUAL Discontinued
EQ 0.4MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.6MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.8MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription

56. Drug name - FINACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8435498 LEO PHARMA AS Penetrating pharmaceutical foam Mar, 2024

(1 year, 5 months from now)

Drugs and Companies using AZELAIC ACID ingredient

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
15% AEROSOL, FOAM;TOPICAL Prescription

57. Drug name - FLONASE SENSIMIST ALLERGY RELIEF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9320862 GLAXOSMITHKLINE CONS Fluid dispensing device Nov, 2024

(2 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.0275MG/SPRAY SPRAY, METERED;NASAL Over the counter

58. Drug name - FOSRENOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions Aug, 2024

(1 year, 10 months from now)

US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE TABLET, CHEWABLE;ORAL Prescription
EQ 250MG BASE TABLET, CHEWABLE;ORAL Discontinued
EQ 500MG BASE TABLET, CHEWABLE;ORAL Prescription
EQ 750MG BASE TABLET, CHEWABLE;ORAL Prescription

59. Drug name - GIVLAARI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(1 year, 3 months from now)

US9708615 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US10273477 ALNYLAM PHARMS INC Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

CN1835897B ALNYLAM PHARMS INC Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank
Aug, 2024

(1 year, 10 months from now)

CN1835897A ALNYLAM PHARMS INC Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank
Aug, 2024

(1 year, 10 months from now)

EP2216407B1 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978A2 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978B1 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978A4 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A3 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A2 ALNYLAM PHARMS INC Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1615611A4 ALNYLAM PHARMS INC Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611B1 ALNYLAM PHARMS INC Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611A2 ALNYLAM PHARMS INC Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1620544A4 ALNYLAM PHARMS INC Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544A2 ALNYLAM PHARMS INC Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544B1 ALNYLAM PHARMS INC Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1765074A2 ALNYLAM PHARMS INC Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1765074A4 ALNYLAM PHARMS INC Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1765074B1 ALNYLAM PHARMS INC Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1667944B1 ALNYLAM PHARMS INC Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1667944A1 ALNYLAM PHARMS INC Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1677822A2 ALNYLAM PHARMS INC 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822A4 ALNYLAM PHARMS INC 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822B1 ALNYLAM PHARMS INC 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

60. Drug name - GRALISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7438927 ALMATICA Methods of treatment using a gastric retained gabapentin dosage Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using GABAPENTIN ingredient

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription

61. Drug name - HYCAMTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645 NOVARTIS Compound, corresponding compositions, preparation and/or treatment methods Dec, 2024

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 1MG BASE CAPSULE;ORAL Prescription

62. Drug name - ILEVRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947295 NOVARTIS Ophthalmic compositions containing a synergistic combination of two polymers Jun, 2024

(1 year, 8 months from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.3% SUSPENSION/DROPS;OPHTHALMIC Prescription

63. Drug name - INBRIJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7182961 ACORDA Particulate compositions for pulmonary delivery Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
42MG POWDER;INHALATION Prescription

64. Drug name - INJECTAFER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7612109 AM REGENT Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM IRON/20ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
750MG IRON/15ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
100MG IRON/2ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
500MG IRON/10ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription

65. Drug name - INVOKAMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound Jul, 2024

(1 year, 9 months from now)

More Information on Dosage
Strength Dosage Availability
50MG;500MG TABLET;ORAL Prescription
50MG;1GM TABLET;ORAL Prescription
150MG;500MG TABLET;ORAL Prescription
150MG;1GM TABLET;ORAL Prescription

66. Drug name - INVOKAMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785403 JANSSEN PHARMS Glucopyranoside compound Jul, 2024

(1 year, 9 months from now)

More Information on Dosage
Strength Dosage Availability
50MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
50MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription

67. Drug name - IONSYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6975902 THE MEDICINES CO Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
EQ 40MCG BASE/ACTIVATION SYSTEM;IONTOPHORESIS, TRANSDERMAL Discontinued

68. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2024

(1 year, 6 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription
EQ 600MG BASE TABLET;ORAL Prescription

69. Drug name - IXEMPRA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7312237 R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using IXABEPILONE ingredient

Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
15MG/VIAL INJECTABLE;INTRAVENOUS Prescription
45MG/VIAL INJECTABLE;INTRAVENOUS Prescription

70. Drug name - KOSELUGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Apr, 2024

(1 year, 6 months from now)

EP1663210A4 ASTRAZENECA N3 Alkylated Benzimidazole Derivatives As Mek Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP1663210A1 ASTRAZENECA Benzimidazole Derivatives As Mek Inhibitors
Aug, 2024

(1 year, 10 months from now)

EP1663210B1 ASTRAZENECA Benzimidazole Derivatives As Mek Inhibitors
Aug, 2024

(1 year, 10 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE CAPSULE;ORAL Prescription
EQ 25MG BASE CAPSULE;ORAL Prescription

71. Drug name - KUVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9433624 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

US8067416 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

US7566714 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders Nov, 2024

(2 years from now)

USRE43797 BIOMARIN PHARM Methods of administering tetrahydrobiopterin Nov, 2024

(2 years from now)

US7612073 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring Nov, 2024

(2 years from now)

US8318745 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride Nov, 2024

(2 years from now)

US7727987 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride Nov, 2024

(2 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Treatment: Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

72. Drug name - KYNMOBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions Feb, 2024

(1 year, 4 months from now)

US8603514 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions Apr, 2024

(1 year, 6 months from now)

More Information on Dosage
Strength Dosage Availability
10MG FILM;SUBLINGUAL Prescription
15MG FILM;SUBLINGUAL Prescription
20MG FILM;SUBLINGUAL Prescription
25MG FILM;SUBLINGUAL Prescription
30MG FILM;SUBLINGUAL Prescription

73. Drug name - LATISSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101161 ALLERGAN Method of enhancing hair growth May, 2024

(1 year, 7 months from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Method of stimulating hair growth; method of increasing hair growth

Dosage: SOLUTION/DROPS;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.03% SOLUTION/DROPS;TOPICAL Prescription

74. Drug name - LATUDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174975 SUNOVION PHARMS INC Remedy for integration dysfunction syndrome Feb, 2024

(1 year, 4 months from now)

US9815827 SUNOVION PHARMS INC Agent for treatment of schizophrenia Feb, 2024

(1 year, 4 months from now)

US9174975

(Pediatric)

SUNOVION PHARMS INC Remedy for integration dysfunction syndrome Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient

Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; treatment of schizophrenia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription
120MG TABLET;ORAL Prescription

75. Drug name - LAZANDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9078814 BTCP PHARMA Intranasal spray device containing pharmaceutical composition Jan, 2024

(1 year, 3 months from now)

US9814705 BTCP PHARMA Intranasal spray device containing pharmaceutical composition Jan, 2024

(1 year, 3 months from now)

US8889176 BTCP PHARMA Method of managing or treating pain Jan, 2024

(1 year, 3 months from now)

US8216604 BTCP PHARMA Method of managing or treating pain Oct, 2024

(2 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: Management of breakthrough pain in patients with cancer

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE SPRAY, METERED;NASAL Prescription
EQ 0.3MG BASE SPRAY, METERED;NASAL Discontinued
EQ 0.4MG BASE SPRAY, METERED;NASAL Prescription

76. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(1 year, 3 months from now)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

CN1835897B NOVARTIS Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank
Aug, 2024

(1 year, 10 months from now)

CN1835897A NOVARTIS Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank
Aug, 2024

(1 year, 10 months from now)

EP2216407B1 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978A2 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978B1 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978A4 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A3 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A2 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1615611A4 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611B1 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611A2 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1620544A4 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544A2 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544B1 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1765074A2 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1765074A4 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1765074B1 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1667944B1 NOVARTIS Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1667944A1 NOVARTIS Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1677822A2 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822A4 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822B1 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

77. Drug name - LINZESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 3 months from now)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 3 months from now)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 3 months from now)

US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(1 year, 3 months from now)

CN101787073B ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

CN101787073A ALLERGAN Method And Composition For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

CN1795007A ALLERGAN Method And Composition For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

CN100589839C ALLERGAN Polypeptide And A Pharmaceutical Composition Comprising The Polypeptide
Jan, 2024

(1 year, 3 months from now)

IN200503394P1 ALLERGAN Methods And Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

IN237521B ALLERGAN A Purified Peptide Which Activates The Guanylate Cyclase C Receptor For Use In Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

EP1911763B1 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

EP1911763A2 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

EP1911763A3 ALLERGAN Compositions For The Treatment Of Gastrointestinal Disorders
Jan, 2024

(1 year, 3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders Jan, 2024

(1 year, 3 months from now)

Drugs and Companies using LINACLOTIDE ingredient

Treatment: Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adults

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
72MCG CAPSULE;ORAL Prescription
145MCG CAPSULE;ORAL Prescription
290MCG CAPSULE;ORAL Prescription

78. Drug name - LIVALO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557993 KOWA CO Crystalline forms of pitavastatin calcium Feb, 2024

(1 year, 4 months from now)

US7022713 KOWA CO Hyperlipemia therapeutic agent Feb, 2024

(1 year, 4 months from now)

US8557993

(Pediatric)

KOWA CO Crystalline forms of pitavastatin calcium Aug, 2024

(1 year, 10 months from now)

US7022713

(Pediatric)

KOWA CO Hyperlipemia therapeutic agent Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using PITAVASTATIN CALCIUM ingredient

Treatment: Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET;ORAL Prescription
EQ 2MG BASE TABLET;ORAL Prescription
EQ 4MG BASE TABLET;ORAL Prescription

79. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7458372 SUNOVION RESP Inhalation therapy device Nov, 2024

(2 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

80. Drug name - LYNPARZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7449464 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(2 years from now)

US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(2 years from now)

CN1788000B ASTRAZENECA Phthalazine Ketone Derivatives
Mar, 2024

(1 year, 5 months from now)

CN1788000A ASTRAZENECA Phthalazinone Derivatives
Mar, 2024

(1 year, 5 months from now)

CN102107008B ASTRAZENECA Dna Damage Repair Inhibitor For The Treatment Of Cancer
Mar, 2024

(1 year, 5 months from now)

CN102107008A ASTRAZENECA Dna Damage Repair Inhibitor For Treatment Of Cancer
Mar, 2024

(1 year, 5 months from now)

CN1905864B ASTRAZENECA For Dna Damage Repair Inhibitors For Treating Cancer
Mar, 2024

(1 year, 5 months from now)

CN1905864A ASTRAZENECA Dna Damage And Repair Inhibitor For Curing Cancer
Mar, 2024

(1 year, 5 months from now)

EP1684736A1 ASTRAZENECA Dna Damage Repair Inhibitors For Treatment Of Cancer
Nov, 2024

(2 years from now)

EP2305221A1 ASTRAZENECA Dna Damage Repair Inhibitors For Treatment Of Cancer
Nov, 2024

(2 years from now)

EP1684736B1 ASTRAZENECA Dna Damage Repair Inhibitors For Treatment Of Cancer
Nov, 2024

(2 years from now)

EP2305221B1 ASTRAZENECA Dna Damage Repair Inhibitors For Treatment Of Cancer
Nov, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8912187 ASTRAZENECA Phthalazinone derivatives Mar, 2024

(1 year, 5 months from now)

US9169235 ASTRAZENECA Phthalazinone derivatives Mar, 2024

(1 year, 5 months from now)

US9566276 ASTRAZENECA Phthalazinone derivatives Mar, 2024

(1 year, 5 months from now)

Drugs and Companies using OLAPARIB ingredient

Treatment: Treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; Treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued

81. Drug name - MAVENCLAD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7888328 EMD SERONO INC Oral formulations of cladribine Apr, 2024

(1 year, 6 months from now)

US8785415 EMD SERONO INC Oral formulations of cladribine Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using CLADRIBINE ingredient

Treatment: Treatment of ms with a tablet with an admixture of (a) an amorphous inclusion complex of cladribine and hydroxypropyl-b-cyclodextrin and (b) amorphous free cladribine and cyclodextrin as a non-inclusion complex, cladribine/cyclodextrin 1:10-1:16 w/w; Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a solid oral form, w/o sign. amounts of cryst. 2cda

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

82. Drug name - MAYZENT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7939519 NOVARTIS Immunosuppresant compounds and compositions
May, 2024

(1 year, 7 months from now)

CN1791395A NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

CN1791395B NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

IN234287B NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

IN200503060P4 NOVARTIS Immunosuppresant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP2514743A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1628967A1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336A2 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP2514743B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1644367B1 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1638551A2 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

EP1633336A4 NOVARTIS Immunosuppressant Compounds And Compositions
May, 2024

(1 year, 7 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription
EQ 2MG BASE TABLET;ORAL Prescription

83. Drug name - MEGACE ES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107827 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

US9101540 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

US7101576 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

US9101549 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

US9040088 ENDO PHARMS INC Nanoparticulate megestrol formulations Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
125MG/ML SUSPENSION;ORAL Prescription

84. Drug name - METHYLIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7691880 SPECGX LLC Methylphenidate solution and associated methods of administration and production Oct, 2024

(2 years from now)

More Information on Dosage
Strength Dosage Availability
5MG/5ML SOLUTION;ORAL Prescription
10MG/5ML SOLUTION;ORAL Prescription

85. Drug name - MIRVASO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders May, 2024

(1 year, 7 months from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 0.33% BASE GEL;TOPICAL Prescription

86. Drug name - MOVANTIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7056500 REDHILL Polymer conjugates of opioid antagonists Jun, 2024

(1 year, 8 months from now)

US8067431 REDHILL Chemically modified small molecules Dec, 2024

(2 years from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

87. Drug name - MOVIPREP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169381 SALIX PHARMS Colon cleansing compositions and methods
Sep, 2024

(1 year, 11 months from now)

US7658914 SALIX PHARMS Colon cleansing compositions
Sep, 2024

(1 year, 11 months from now)

More Information on Dosage
Strength Dosage Availability
4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM FOR SOLUTION;ORAL Prescription

88. Drug name - MULPLETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(1 year, 11 months from now)

CN103130739B SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN102796058B SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN103130739A SHIONOGI INC Compound With Thrombopoietin Receptor Agonist Action
Aug, 2024

(1 year, 10 months from now)

CN102796058A SHIONOGI INC Compound Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

IN232700B SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

IN200600512P4 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291B1 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291A1 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

EP1655291A4 SHIONOGI INC Compounds Having Thrombopoietin Receptor Agonism
Aug, 2024

(1 year, 10 months from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

89. Drug name - MYFEMBREE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(1 year, 3 months from now)

US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(1 year, 3 months from now)

CN100360538C MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

CN1768065A MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

IN235678B MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

IN200501636P2 MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

EP1591446A4 MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

EP1591446A1 MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

EP1591446B1 MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG;0.5MG;40MG TABLET;ORAL Prescription

90. Drug name - MYRBETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient May, 2024

(1 year, 7 months from now)

USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient May, 2024

(1 year, 7 months from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative May, 2024

(1 year, 7 months from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative May, 2024

(1 year, 7 months from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription

91. Drug name - MYRBETRIQ GRANULES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative May, 2024

(1 year, 7 months from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative May, 2024

(1 year, 7 months from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

92. Drug name - NAROPIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8162915 FRESENIUS KABI USA Connector for packings containing medical liquids, and corresponding packing for medical liquids May, 2024

(1 year, 7 months from now)

More Information on Dosage
Strength Dosage Availability
1GM/200ML (5MG/ML) SOLUTION;INJECTION Prescription
50MG/10ML (5MG/ML) SOLUTION;INJECTION Discontinued
20MG/10ML (2MG/ML) SOLUTION;INJECTION Prescription
40MG/20ML (2MG/ML) SOLUTION;INJECTION Prescription
75MG/10ML (7.5MG/ML) SOLUTION;INJECTION Discontinued
100MG/20ML (5MG/ML) SOLUTION;INJECTION Prescription
100MG/10ML (10MG/ML) SOLUTION;INJECTION Prescription
150MG/20ML (7.5MG/ML) SOLUTION;INJECTION Prescription
150MG/30ML (5MG/ML) SOLUTION;INJECTION Prescription
200MG/100ML (2MG/ML) SOLUTION;INJECTION Prescription
200MG/20ML (10MG/ML) SOLUTION;INJECTION Prescription
400MG/200ML (2MG/ML) SOLUTION;INJECTION Prescription
500MG/100ML (5MG/ML) SOLUTION;INJECTION Prescription

93. Drug name - NASCOBAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940714 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Feb, 2024

(1 year, 4 months from now)

US7404489 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Mar, 2024

(1 year, 5 months from now)

US9415007 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Jul, 2024

(1 year, 9 months from now)

US8003353 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Aug, 2024

(1 year, 10 months from now)

US7879349 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Aug, 2024

(1 year, 10 months from now)

US7229636 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using CYANOCOBALAMIN ingredient

Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.5MG/SPRAY SPRAY, METERED;NASAL Prescription

94. Drug name - NATESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784882 ACERUS Controlled release delivery system for nasal applications and method of treatment Feb, 2024

(1 year, 4 months from now)

US8784869 ACERUS Controlled release delivery system for nasal applications and methods of treatment Feb, 2024

(1 year, 4 months from now)

US8574622 ACERUS Controlled release delivery system for nasal applications Feb, 2024

(1 year, 4 months from now)

US8877230 ACERUS Controlled release delivery system for nasal applications Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation.; Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
5.5MG/0.122GM ACTUATION GEL, METERED;NASAL Prescription

95. Drug name - NINLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546608 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 10 months from now)

CN1867572A TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Use Thereof
Aug, 2024

(1 year, 10 months from now)

CN1867572B TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Use Thereof
Aug, 2024

(1 year, 10 months from now)

IN200600565P2 TAKEDA PHARMS USA Boronic Acid And Ester Compounds, Pharmaceutical Compounds Comprising Them And Process For Their Preparation
Aug, 2024

(1 year, 10 months from now)

IN231455B TAKEDA PHARMS USA Boronic Acid And Ester Compounds, Pharmaceutical Compounds Comprising Them And Process For Their Preparation .
Aug, 2024

(1 year, 10 months from now)

EP1660507B2 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507B1 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507B9 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507A2 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using IXAZOMIB CITRATE ingredient

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.3MG BASE CAPSULE;ORAL Prescription
EQ 3MG BASE CAPSULE;ORAL Prescription
EQ 4MG BASE CAPSULE;ORAL Prescription

96. Drug name - NOCDURNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560429 FERRING PHARMS INC Orodispersible dosage forms of desmopressin acetate Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: Treatment of nocturia due to nocturnal polyuria in adults

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
0.0277MG TABLET;SUBLINGUAL Prescription
0.0553MG TABLET;SUBLINGUAL Prescription

97. Drug name - NOCTIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799761 SERENITY PHARMS LLC Pharmaceutical compositions including low dosages of desmopressin Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.00083MG/SPRAY SPRAY, METERED;NASAL Discontinued
0.00166MG/SPRAY SPRAY, METERED;NASAL Discontinued

98. Drug name - NOURIANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7541363 KYOWA KIRIN Microcrystal
Nov, 2024

(2 years from now)

CN1784405A KYOWA KIRIN Microcrystalline
May, 2024

(1 year, 7 months from now)

CN100395245C KYOWA KIRIN Microcrystalline
May, 2024

(1 year, 7 months from now)

EP1626049A1 KYOWA KIRIN Microcrystal Of (E)-8-(3,4-Dimethoxystyryl)-1,3-Diethyl-7-Methyl-3,7-Dihydro-1H-Purine-2,6-Dione
May, 2024

(1 year, 7 months from now)

EP1626049A4 KYOWA KIRIN Microcrystal
May, 2024

(1 year, 7 months from now)

EP1626049B1 KYOWA KIRIN Microcrystal Of (E)-8-(3,4-Dimethoxystyryl)-1,3-Diethyl-7-Methyl-3,7-Dihydro-1H-Purine-2,6-Dione
May, 2024

(1 year, 7 months from now)

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription

99. Drug name - NUCYNTA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383 COLLEGIUM PHARM INC Abuse-proofed dosage form Oct, 2024

(2 years from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 250MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

100. Drug name - NUPLAZID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618130 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Jan, 2024

(1 year, 3 months from now)

US9566271 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Jan, 2024

(1 year, 3 months from now)

US10028944 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Jan, 2024

(1 year, 3 months from now)

US8921393 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Jan, 2024

(1 year, 3 months from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Treatment: Treatment of psychosis or a symptom thereof; Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 34MG BASE CAPSULE;ORAL Prescription

101. Drug name - NUVIGIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil May, 2024

(1 year, 7 months from now)

US7132570

(Pediatric)

CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil Jun, 2024

(1 year, 8 months from now)

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Discontinued
150MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription
250MG TABLET;ORAL Prescription

102. Drug name - NYMALIZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8517997 ARBOR PHARMS LLC Dispenser for medicaments and method and apparatus for making same May, 2024

(1 year, 7 months from now)

Drugs and Companies using NIMODIPINE ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
3MG/ML SOLUTION;ORAL Discontinued
6MG/ML SOLUTION;ORAL Prescription

103. Drug name - OFEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(1 year, 4 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

104. Drug name - OMEGAVEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN) Nov, 2024

(2 years from now)

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
5GM/50ML (0.1GM/ML) EMULSION;INTRAVENOUS Prescription
10GM/100ML (0.1GM/ML) EMULSION;INTRAVENOUS Prescription

105. Drug name - OMIDRIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173707

(Pediatric)

RAYNER SURGICAL Ophthalmologic irrigation solutions and method Jan, 2024

(1 year, 4 months from now)

US8586633

(Pediatric)

RAYNER SURGICAL Ophthalmologic irrigation solutions and method Jan, 2024

(1 year, 4 months from now)

US9278101

(Pediatric)

RAYNER SURGICAL Ophthalmologic irrigation solutions and method Jan, 2024

(1 year, 4 months from now)

US9399040

(Pediatric)

RAYNER SURGICAL Ophthalmologic irrigation solutions and method Jan, 2024

(1 year, 4 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.3% BASE;EQ 1% BASE SOLUTION;IRRIGATION Prescription

106. Drug name - OMONTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(1 year, 7 months from now)

US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

IN200502499P2 TAKEDA PHARMS USA A Peptide Dimer
May, 2024

(1 year, 7 months from now)

IN224732B TAKEDA PHARMS USA A Peptide Dimer
May, 2024

(1 year, 7 months from now)

IN200502493P2 TAKEDA PHARMS USA A Peptide Cross-Reference To Related Applications
May, 2024

(1 year, 7 months from now)

IN228387B TAKEDA PHARMS USA A Peptide
May, 2024

(1 year, 7 months from now)

EP1629007B1 TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1625156B1 TAKEDA PHARMS USA Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1629007A2 TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1625156A2 TAKEDA PHARMS USA Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued

107. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119932 CURRAX Nasal delivery device Apr, 2024

(1 year, 6 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

108. Drug name - OPANA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114383 ENDO PHARMS Abuse-proofed dosage form Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
7.5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG TABLET, EXTENDED RELEASE;ORAL Discontinued
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
20MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
40MG TABLET, EXTENDED RELEASE;ORAL Discontinued

109. Drug name - ORACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709478 GALDERMA LABS LP Once daily formulations of tetracyclines Apr, 2024

(1 year, 6 months from now)

US8470364 GALDERMA LABS LP Once daily formulations of tetracyclines Apr, 2024

(1 year, 6 months from now)

US8394405 GALDERMA LABS LP Once daily formulations of tetracyclines Apr, 2024

(1 year, 6 months from now)

US8394406 GALDERMA LABS LP Once daily formulations of tetracyclines Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using DOXYCYCLINE ingredient

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Prescription

110. Drug name - ORENITRAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050311 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 7 months from now)

CN101265226A UNITED THERAP Compound And Method For Delivery Of Prostacyclin Analogueue
May, 2024

(1 year, 7 months from now)

CN101780092B UNITED THERAP Compounds And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN100558351C UNITED THERAP Composition And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN101265226B UNITED THERAP Composition And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN101780092A UNITED THERAP Compound And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

CN1822826A UNITED THERAP Compounds And Method For Releasing Prostacyclin Analogue
May, 2024

(1 year, 7 months from now)

IN200502621P2 UNITED THERAP An Oral Pharmaceutical Composition
May, 2024

(1 year, 7 months from now)

IN247151B UNITED THERAP An Oral Pharmaceutical Composition
May, 2024

(1 year, 7 months from now)

EP1628654B1 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP1628654A4 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP2792353A3 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP1628654A2 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

EP2792353B1 UNITED THERAP Polymorph Of Treprostinil Diethanolamine Salt
May, 2024

(1 year, 7 months from now)

EP2792353A2 UNITED THERAP Polymorph Of Treprostinil Diethanolamine Salt
May, 2024

(1 year, 7 months from now)

EP1628654B2 UNITED THERAP Compounds And Methods For Delivery Of Prostacyclin Analogs
May, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9422223 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US9278901 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US8252839 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US7544713 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs Jul, 2024

(1 year, 9 months from now)

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.125MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 0.25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

111. Drug name - ORGOVYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(1 year, 3 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(1 year, 3 months from now)

CN100360538C MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

CN1768065A MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

IN235678B MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

IN200501636P2 MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

EP1591446A4 MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

EP1591446A1 MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

EP1591446B1 MYOVANT SCIENCES Thienopyrimidine Compounds And Use Thereof
Jan, 2024

(1 year, 3 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using RELUGOLIX ingredient

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
120MG TABLET;ORAL Prescription

112. Drug name - ORIAHNN (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 9 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 11 months from now)

CN100424078C ABBVIE INC As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives
Jul, 2024

(1 year, 9 months from now)

CN1819829A ABBVIE INC As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives
Jul, 2024

(1 year, 9 months from now)

IN200600072P1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

IN312234B ABBVIE INC Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

EP1646389A1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

EP1646389B1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE CAPSULE;ORAL Prescription

113. Drug name - ORILISSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2024

(1 year, 9 months from now)

US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(1 year, 11 months from now)

CN100424078C ABBVIE INC As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives
Jul, 2024

(1 year, 9 months from now)

CN1819829A ABBVIE INC As Gonadotropin-Releasing Hormone Receptor Antagonists And -2 - 4-Dione Derivatives
Jul, 2024

(1 year, 9 months from now)

IN200600072P1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

IN312234B ABBVIE INC Pyrimidine-2, 4-Dione Based Compounds As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

EP1646389A1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

EP1646389B1 ABBVIE INC Pyrimidine-2,4-Dione Derivatives As Gonadotropin-Releasing Hormone Receptor Antagonists
Jul, 2024

(1 year, 9 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto Jul, 2024

(1 year, 9 months from now)

Drugs and Companies using ELAGOLIX SODIUM ingredient

Treatment: Management of moderate to severe pain associated with endometriosis

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription
EQ 200MG BASE TABLET;ORAL Prescription

114. Drug name - OSPHENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470890 DUCHESNAY Method for enhancing the bioavailability of ospemifene Feb, 2024

(1 year, 4 months from now)

US9241915 DUCHESNAY Method for enhancing the bioavailability of ospemifene Feb, 2024

(1 year, 4 months from now)

US9855224 DUCHESNAY Method for enhancing the bioavailability of ospemifene Feb, 2024

(1 year, 4 months from now)

US8772353 DUCHESNAY Method for enhancing the bioavalability of ospemifene Feb, 2024

(1 year, 4 months from now)

Drugs and Companies using OSPEMIFENE ingredient

Treatment: Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of dyspareunia associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; treatment of dyspareunia associated with menopause; treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; Treatment of dyspareunia associated with menopause; treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

115. Drug name - OXAYDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492443 ZYLA Abuse deterrent compositions and methods of making same May, 2024

(1 year, 7 months from now)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
7.5MG TABLET;ORAL Prescription

116. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7762994 NOVO Needle mounting system and a method for mounting a needle assembly May, 2024

(1 year, 7 months from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/1.5ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription
4MG/3ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription

117. Drug name - PONVORY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728 JANSSEN PHARMS Thiazolidin-4-one derivatives
Nov, 2024

(2 years from now)

IN254201B JANSSEN PHARMS Novel Thiazolidin-4-One Derivatives
Nov, 2024

(2 years from now)

IN200602225P4 JANSSEN PHARMS Novel Thiazoldin-4-One Derivatives
Nov, 2024

(2 years from now)

EP1689726A1 JANSSEN PHARMS 5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents
Nov, 2024

(2 years from now)

EP1689726B1 JANSSEN PHARMS 5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents
Nov, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018 JANSSEN PHARMS Thiazolidin-4-one-derivatives Nov, 2024

(2 years from now)

Drugs and Companies using PONESIMOD ingredient

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

118. Drug name - PREVYMIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 7 months from now)

US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 7 months from now)

CN100393706C MERCK SHARP DOHME Substituted Dihydroquinazolin Having Anti-Virus Capability
Apr, 2024

(1 year, 6 months from now)

CN1784390A MERCK SHARP DOHME Substituted Dihydroquinazolin Having Anti-Virus Capability
Apr, 2024

(1 year, 6 months from now)

IN200504403P1 MERCK SHARP DOHME Substituted Dihydroquinazolines
Apr, 2024

(1 year, 6 months from now)

IN230768B MERCK SHARP DOHME Substituted Dihydroquinazoline Compounds
Apr, 2024

(1 year, 6 months from now)

EP1622880B3 MERCK SHARP DOHME Substituted Dihydrochinazolines Having Antiviral Properties
Apr, 2024

(1 year, 6 months from now)

EP1622880A1 MERCK SHARP DOHME Substituted Dihydrochinazolines Having Antiviral Properties
Apr, 2024

(1 year, 6 months from now)

EP1622880B1 MERCK SHARP DOHME Substituted Dihydrochinazolines Having Antiviral Properties
Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using LETERMOVIR ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
240MG/12ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription
480MG/24ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription

119. Drug name - PREZCOBIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(1 year, 4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor Aug, 2024

(1 year, 10 months from now)

More Information on Dosage
Strength Dosage Availability
150MG;800MG TABLET;ORAL Prescription

120. Drug name - PREZISTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(1 year, 4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using DARUNAVIR ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/ML SUSPENSION;ORAL Prescription

121. Drug name - PRIALT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765680 TERSERA Method for administering omega-conopeptide Oct, 2024

(2 years from now)

US8653033 TERSERA Method for administering omega-conopeptide Oct, 2024

(2 years from now)

US9707270 TERSERA Method for administering ω-conopeptide Oct, 2024

(2 years from now)

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Treatment: Treatment of pain; analgesia; Analgesia; treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine

Dosage: INJECTABLE;INTRATHECAL

More Information on Dosage
Strength Dosage Availability
100MCG/1ML (100MCG/ML) INJECTABLE;INTRATHECAL Prescription
200MCG/2ML (100MCG/ML) INJECTABLE;INTRATHECAL Discontinued
500MCG/20ML (25MCG/ML) INJECTABLE;INTRATHECAL Prescription
500MCG/5ML (100MCG/ML) INJECTABLE;INTRATHECAL Prescription

122. Drug name - PROBUPHINE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7736665 TITAN PHARMS Implantable polymeric device for sustained release of buprenorphine Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Treatment: For opioid dependence

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage
Strength Dosage Availability
EQ 80MG BASE/IMPLANT IMPLANT;IMPLANTATION Discontinued

123. Drug name - PROLENSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871813 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US8754131 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US8669290 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US9144609 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US8927606 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

US9561277 BAUSCH AND LOMB Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid Jan, 2024

(1 year, 3 months from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: Method of treating ocular inflammation; method of treating ocular inflammation; method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.07% ACID SOLUTION/DROPS;OPHTHALMIC Prescription

124. Drug name - PROTONIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7553498 WYETH PHARMS Pantoprazole multiparticulate formulations Sep, 2024

(2 years from now)

US7550153 WYETH PHARMS Pantoprazole multiparticulate formulations Sep, 2024

(2 years from now)

US7838027 WYETH PHARMS Pantoprazole multiparticulate formulations Sep, 2024

(2 years from now)

Drugs and Companies using PANTOPRAZOLE SODIUM ingredient

Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd

Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE FOR SUSPENSION, DELAYED RELEASE;ORAL Prescription

125. Drug name - PROVIGIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil May, 2024

(1 year, 7 months from now)

Drugs and Companies using MODAFINIL ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

126. Drug name - RAYOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309124 HORIZON Delayed release tablet with defined core geometry Apr, 2024

(1 year, 6 months from now)

US9186332 HORIZON Delayed release tablet with defined core geometry Apr, 2024

(1 year, 6 months from now)

US9040085 HORIZON Delayed release tablet with defined core geometry Apr, 2024

(1 year, 6 months from now)

US8394407 HORIZON Delayed release tablet with defined core geometry Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using PREDNISONE ingredient

Treatment: Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET, DELAYED RELEASE;ORAL Prescription
2MG TABLET, DELAYED RELEASE;ORAL Prescription
5MG TABLET, DELAYED RELEASE;ORAL Prescription

127. Drug name - RELISTOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8552025 SALIX PHARMS Stable methylnaltrexone preparation Apr, 2024

(1 year, 6 months from now)

US9669096 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone Apr, 2024

(1 year, 6 months from now)

US10376584 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone Apr, 2024

(1 year, 6 months from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
8MG/0.4ML (8MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
12MG/0.6ML (12MG/0.6ML) SOLUTION;SUBCUTANEOUS Prescription

128. Drug name - REMODULIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs May, 2024

(1 year, 7 months from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil Dec, 2024

(2 years from now)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil Dec, 2024

(2 years from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil Dec, 2024

(2 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
2.5MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
5MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
10MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription
20MG/ML INJECTABLE;IV (INFUSION), SUBCUTANEOUS Prescription

129. Drug name - RESTASIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642556 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8629111 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8633162 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8648048 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8685930 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US9248191 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.05% EMULSION;OPHTHALMIC Prescription

130. Drug name - REVLIMID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7855217 CELGENE Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
Nov, 2024

(2 years from now)

EP2426118A1 CELGENE Methods Of Making Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 11 months from now)

EP3045176B8 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 11 months from now)

EP2426118B1 CELGENE Methods Of Making Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 11 months from now)

EP3045176A1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 11 months from now)

EP3045176B1 CELGENE Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione
Sep, 2024

(1 year, 11 months from now)

Drugs and Companies using LENALIDOMIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG CAPSULE;ORAL Prescription
5MG CAPSULE;ORAL Prescription
10MG CAPSULE;ORAL Prescription
15MG CAPSULE;ORAL Prescription
20MG CAPSULE;ORAL Prescription
25MG CAPSULE;ORAL Prescription

131. Drug name - RHOFADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8815929 EPI HLTH Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists